SCHEMBL14764615

SCHEMBL14764615

Cc1ccc2nc(Cl)c(C)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.57
KDM4E B2RXH2 5/20 0.56
MAPT P10636 5/20 0.56
ALDH1A1 P00352 5/20 0.51
KMT2A Q03164 4/20 0.49
NPSR1 Q6W5P4 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 3/20 0.44
USP2 O75604 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 1/20 0.44
PABPC1 P11940 1/20 0.44
RAB9A P51151 2/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 2/20 0.42
PSMB5 P28074 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14764426 1.00 NQO2 (0.57) NQO2KDM4EMAPTALDH1A1KMT2A
SCHEMBL404199 0.89 NQO2 (0.64) NQO2KDM4EMAPTALDH1A1KMT2A
SCHEMBL30745612 0.84 NQO2 (0.70) NQO2KDM4EMAPTALDH1A1KMT2A
SCHEMBL434975 0.84 NQO2 (0.70) NQO2KDM4EMAPTALDH1A1KMT2A
SCHEMBL6303670 0.83 KMT2A (0.62) KDM4EMAPTALDH1A1KMT2ATDP1
SCHEMBL6311061 0.83 KMT2A (0.62) KDM4EMAPTALDH1A1KMT2ATDP1
SCHEMBL13077444 0.80 NQO2 (0.53) NQO2KDM4EMAPTALDH1A1KMT2A
SCHEMBL1138054 0.80 NQO2 (0.53) NQO2KDM4EMAPTALDH1A1KMT2A
SCHEMBL12503088 0.80 RXFP1 (0.49) KDM4EMAPTALDH1A1KMT2ATDP1
SCHEMBL2178248 0.80 KDM4E (0.48) KDM4EMAPTALDH1A1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4400505-A1 PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF Bivision Pharmaceuticals, Inc (CN) 2024-07-17 EP disclosed
US-20140147386-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
WO-2013034755-A1 TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS H. LUNDBECK A/S (DK) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140147386-A1 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES PDE2A, PDE12, PDE5A NQO2 85/4885KDM4E 435/4885MAPT 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.